
Lawmakers unite to condemn pharmacists for high prices in the U.S.
Los legisladores culpan a los gestores de prestaciones farmacéuticas de los elevados precios de los medicamentos en Estados Unidos.

During a recent congressional oversight committee meeting, both Democratic and Republican representatives united in holding executives from three of the largest pharmacy benefit managers (PBMs) accountable for the exorbitant prices of prescription drugs in the United States. The leaders of these PBMs, namely CVS Caremark, Cigna’s Express Scripts, and UnitedHealth Group’s OptumRx, were sharply criticized for their alleged role in inflating drug costs and impeding access to necessary medications.
The House Committee on Oversight and Accountability convened to address the escalating concerns related to the soaring prices of prescription drugs. The hearing followed the release of a damning report by the Federal Trade Commission (FTC), which accused the three PBMs of amassing substantial profits by directing patients and employers toward higher-priced drugs. The testimonies and evidence presented during the hearing shed light on the profound impact of expensive prescription drugs on individuals across the country.
Share news